Theravance Biopharma, Inc.
DE ˙ DB ˙ KYG8807B1068
13,90 € ↑0,30 (2,21%)
2026-06-05
DEL PRIS
SecurityDE:0TB / Theravance Biopharma, Inc.
InstitutionJane Street Group, Llc
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Jane Street Group, Llc ownership in 0TB / Theravance Biopharma, Inc.

On May 12, 2026 - Jane Street Group, Llc filed a 13F-HR form disclosing ownership of 0 shares of Theravance Biopharma, Inc. (DE:0TB) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 55,831 shares of Theravance Biopharma, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Jane Street Group, Llc has a history of taking positions in derivatives of the underlying security (0TB) in the form of stock options. The firm currently holds call options representing 17,200 of underlying shares valued at $279,156 USD and put options representing 13,900 of underlying shares valued at $225,597 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:0TB / Theravance Biopharma, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 0 -55,831 -100.00 0 -100.00
2026-02-12 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 55,831 -135,966 -70.89 1,045 -62.71 0.0002
2025-11-14 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 191,797 149,033 348.50 2,800 494.48 0.0004
2025-08-14 2025-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 42,764 -98,120 -69.65 472 -62.56 0.0001
2025-05-19 2025-03-31 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 140,884 88,540 169.15 1,258 155.69 0.0003
2025-05-14 2025-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 140,884 88,540 1,258 0.0003
2025-02-14 2024-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 52,344 -92,231 -63.79 493 -57.77 0.0001
2024-11-15 2024-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 144,575 1,640 1.15 1,165 -3.88 0.0003
2024-08-15 2024-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 142,935 109,327 325.30 1,212 302.66 0.0003
2024-05-16 2024-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 33,608 -337,909 -90.95 301 -92.79 0.0001
2024-02-15 2023-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 371,517 -87,994 -19.15 4,176 5.30 0.0011
2023-11-15 2023-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 459,511 33,091 7.76 3,966 -10.15 0.0013
2023-08-14 2023-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 426,420 303,654 247.34 4,413 231.31 0.0015
2023-05-16 2023-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 122,766 -23,388 -16.00 1,332 -18.73 0.0005
2023-02-15 2022-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 146,154 -43,793 -23.06 1,640 -14.90 0.0008
2022-11-15 2022-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 189,947 103,214 119.00 1,926 145.04 0.0008
2022-08-16 2022-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 86,733 -36,601 -29.68 786 -33.39 0.0003
2022-05-17 2022-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 123,334 70,068 131.54 1,180 100.34 0.0004
2022-02-15 2021-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 53,266 38,820 268.72 589 450.47 0.0002
2021-11-16 2021-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 14,446 14,446 107 0.0000
2021-08-16 2021-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 0 -14,192 -100.00 0 -100.00
2021-05-18 2021-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 14,192 14,192 290 0.0001
2021-02-17 2020-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 0 -21,140 -100.00 0 -100.00
2020-11-17 2020-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 21,140 -1,197,772 -98.27 313 -98.78 0.0002
2020-08-17 2020-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 1,218,912 1,218,912 5,665.90 25,585 8,074.12 0.0192
2018-08-15 2018-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 0 -141,329 -100.00 0 -100.00
2018-05-15 2018-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 141,329 141,329 3,427 0.0089
2016-08-15 2016-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 0 -10,584 -100.00 0 -100.00
2016-05-17 2016-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 10,584 10,584 199 0.0011
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-12 2026-03-31 13F THERAVANCE BIOPHARMA COM Call 17,200 3.61 279 -10.00 n/a n/a n/a
2026-02-12 2025-12-31 13F THERAVANCE BIOPHARMA COM Call 16,600 20.29 311 54.23 n/a n/a n/a
2025-11-14 2025-09-30 13F THERAVANCE BIOPHARMA COM Call 13,800 201 n/a n/a n/a
2023-05-15 2023-03-31 13F THERAVANCE BIOPHARMA COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-02-15 2022-12-31 13F THERAVANCE BIOPHARMA COM Call 105,600 1,185 n/a n/a n/a
2022-11-14 2022-09-30 13F THERAVANCE BIOPHARMA COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-08-16 2022-06-30 13F THERAVANCE BIOPHARMA COM Call 30,400 275 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-12 2026-03-31 13F THERAVANCE BIOPHARMA COM Put 13,900 226 n/a n/a n/a
2026-02-12 2025-12-31 13F THERAVANCE BIOPHARMA COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-11-14 2025-09-30 13F THERAVANCE BIOPHARMA COM Put 101,100 1,476 n/a n/a n/a
2023-08-14 2023-06-30 13F THERAVANCE BIOPHARMA COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-05-16 2023-03-31 13F THERAVANCE BIOPHARMA COM Put 13,200 -23.26 143 -25.52 n/a n/a n/a
2023-02-15 2022-12-31 13F THERAVANCE BIOPHARMA COM Put 17,200 -15.69 193 -7.25 n/a n/a n/a
2022-11-15 2022-09-30 13F THERAVANCE BIOPHARMA COM Put 20,400 -36.25 207 -28.62 n/a n/a n/a
2022-08-16 2022-06-30 13F THERAVANCE BIOPHARMA COM Put 32,000 -90.96 290 -91.43 n/a n/a n/a
2022-05-17 2022-03-31 13F THERAVANCE BIOPHARMA COM Put 354,100 3,385 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.